{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:56:55Z","timestamp":1792634215809,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1038\/s41375-019-0655-x","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T17:02:42Z","timestamp":1574442162000},"page":"1135-1143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lisa Hwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Zeldenrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"655_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Schonland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Prim. 2018;4:38.","journal-title":"Nat Rev Dis Prim"},{"key":"655_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/13506129.2018.1443439","volume":"25","author":"N Tovar","year":"2018","unstructured":"Tovar N, Rodriguez-Lobato LG, Cibeira MT, Magnano L, Isola I, Rosinol L, et al. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. Amyloid. 2018;25:79\u201385.","journal-title":"Amyloid"},{"key":"655_CR3","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129:2111\u20139.","journal-title":"Blood"},{"key":"655_CR4","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","volume":"31","author":"TV Kourelis","year":"2013","unstructured":"Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31:4319\u201324.","journal-title":"J Clin Oncol"},{"key":"655_CR5","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013548.","journal-title":"Lancet Oncol"},{"key":"655_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319\u201328.","journal-title":"Am J Hematol"},{"key":"655_CR7","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751\u20137.","journal-title":"J Clin Oncol"},{"key":"655_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989\u201395.","journal-title":"J Clin Oncol"},{"key":"655_CR9","doi-asserted-by":"crossref","unstructured":"Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, et al. Interphase fluorescence in-situ hybridization (iFISH) in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31:1562\u20139.","DOI":"10.1038\/leu.2016.369"},{"key":"655_CR10","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0025-6196(12)65066-6","volume":"62","author":"PR Greipp","year":"1987","unstructured":"Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O\u2019Fallon WM, et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc. 1987;62:969\u201377.","journal-title":"Mayo Clin Proc"},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3324\/haematol.2018.189985","volume":"103","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, et al. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica. 2018;103:1229\u201334.","journal-title":"Haematologica"},{"key":"655_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/leu.2016.140","volume":"31","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, et al. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia. 2017;31:92\u201399.","journal-title":"Leukemia"},{"key":"655_CR13","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541\u20139.","journal-title":"J Clin Oncol"},{"key":"655_CR14","doi-asserted-by":"crossref","unstructured":"Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain (AL) amyloidosis. Blood. 2019;133:215\u201323.","DOI":"10.1182\/blood-2018-06-858951"},{"key":"655_CR15","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","volume":"107","author":"G Palladini","year":"2003","unstructured":"Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440\u20135.","journal-title":"Circulation"},{"key":"655_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/10428190701684518","volume":"49","author":"M Gertz","year":"2008","unstructured":"Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma. 2008;49:36\u201341.","journal-title":"Leuk Lymphoma"},{"key":"655_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","volume":"33","author":"T Bochtler","year":"2015","unstructured":"Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33:1371\u20138.","journal-title":"J Clin Oncol"},{"key":"655_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.34","volume":"5","author":"R Warsame","year":"2015","unstructured":"Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015;5:e310.","journal-title":"Blood Cancer J"},{"key":"655_CR19","doi-asserted-by":"crossref","unstructured":"Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018;32:2240\u20139.","DOI":"10.1038\/s41375-018-0060-x"},{"key":"655_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","volume":"130","author":"T Dittrich","year":"2017","unstructured":"Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130:632\u201342.","journal-title":"Blood"},{"key":"655_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","volume":"130","author":"P Milani","year":"2017","unstructured":"Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130:625\u201331.","journal-title":"Blood"},{"key":"655_CR22","doi-asserted-by":"crossref","unstructured":"Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2018;32:729\u201335.","DOI":"10.1038\/leu.2017.286"},{"key":"655_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","volume":"123","author":"MV Dhodapkar","year":"2014","unstructured":"Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014;123:78\u201385.","journal-title":"Blood"},{"key":"655_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.","journal-title":"Blood Cancer J"},{"key":"655_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group.","year":"2003","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749\u201357.","journal-title":"Br J Haematol"}],"updated-by":[{"DOI":"10.1038\/s41375-020-0993-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0655-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0655-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0655-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:38:39Z","timestamp":1684618719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0655-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0655-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41375-020-0993-8","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-020-0993-8","URL":"https:\/\/doi.org\/10.1038\/s41375-020-0993-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"EM: None; MAG: Consultancy (Milleniu) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis). TVK: None; SS: None; RSG: None; MQL: Research funding (Celgene); FB: None; DD: Research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); SRH: None; PK: Research funding (Takeda, Celgene, and Amgen); NL: None; AF: None; MH: None; YLH: None; WG: None; RW: None; SR: None; JAL: None; YL: None; SZ: None; SVR: None; RAK: None; SKK: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS); and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). AD: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}